Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Supreme Court Verdict In Patent Case Could Cause ‘Unprecedented Nightmare Scenario’ For Industry

The justices may find the role of administrative judges unconstitutional

Executive Summary

A challenge to the US patent appeals system taken up by the Supreme Court could create a crisis for medtech companies with patents under review, attorneys tell Medtech Insight.

You may also be interested in...



Attorney: Expect PTO Director To Use ‘Discretion’ In New Patent Appeal Authority

The US Supreme Court found that the role of administrative judges in patent review was unconstitutional but could be fixed by giving the PTO’s director more oversight, reinforcing the staying power of the patent appeals process.

'Super Dramatic' Ruling On PTAB Judges' Unconstitutional Status Will Have 'Limited Fallout'

Patent owners can challenge US Patent and Trial and Appeal Board's decisions on grounds the judges were not constitutionally appointed in a narrow number of cases, but they may have difficulty winning a different outcome.

Inter Partes Patent Challenges Are Constitutional, US Supreme Court Rules

IPR process can continue, but the Patent Trial and Appeals Board must issue a final written decision on all claims raised by the challenger – not just some of them, court says; rulings in two closely watched cases mean that IPR proceedings can continue unabated, but challengers may need to rethink how they go about challenging innovator patent claims.

Topics

Latest News
UsernamePublicRestriction

Register

MT143260

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel